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ORIGINAL ARTICLE Open Access
Investigation into cardiac sympathetic
innervation during the commencement of
haemodialysis in patients with chronic
kidney disease
Walter Noordzij1* , Akin Özyilmaz2,3, Andor W. J. M. Glaudemans1, René A. Tio4, Esther R. Goet2,3,
Casper F. M. Franssen2 and Riemer H. J. A. Slart1
Abstract
Background: Patients with chronic kidney disease (CKD) who undergo chronic haemodialysis (HD) show altered
sympathetic tone, which is related to a higher cardiovascular mortality. The purpose of this study was to investigate
the effect of transition from pre-HD to HD on cardiac sympathetic innervation.
Methods: Eighteen patients aged 58 ± 18 years (mean ± standard deviation [SD]), 13 males and five females,
with stage 5 CKD and nine healthy control subjects aged 52 ± 17 (mean ± SD), three males and six females, were
included in this prospective study between May 2010 and December 2013. All patients underwent 123I-labelled
meta-iodobenzylguanidine (123I-MIBG) scintigraphy for cardiac sympathetic innervation and electrocardiographically
gated adenosine stress and rest 99mTc-labelled tetrofosmin single-photon emission computed tomography
for myocardial perfusion imaging prior to (pre-HD) and 6 months after the start of HD. Results of 123I-MIBG
scans in patients were compared to controls. Impaired cardiac sympathetic innervation was defined as late
heart-to-mediastinum ratio (HMR) < 2.0.
Results: Mean late HMR was lower in patients during HD (2.3) than in controls (2.9) (p = 0.035); however, in
patients it did not differ between pre-HD and after the start of HD. During HD, two patients showed new
sympathetic innervation abnormalities, and in three patients innervation abnormalities seemed to coincide
with myocardial perfusion abnormalities.
Conclusions: CKD patients show cardiac sympathetic innervation abnormalities, which do not seem to
progress during the maintenance HD. The relationship between sympathetic innervation abnormalities and
myocardial perfusion abnormalities in HD patients needs further exploration.
Keywords: Chronic kidney disease, Haemodialysis, Myocardial ischaemia, Myocardial scintigraphy, Sympathetic
innervation
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Key points
 End-stage renal disease patients on maintenance
haemodialysis have lower mean late heart-to-
mediastinum ratio on 123I-labelled meta-
iodobenzylguanidine scintigraphy than healthy
control subjects
 Mean late heart-to-mediastinum ratio does not seem
to worsen during the commencement of maintenance
haemodialysis
 Patients with signs of cardiac sympathetic innervation
abnormalities before the start of haemodialysis
developed alterations in myocardial perfusion during
haemodialysis
Background
Chronic kidney disease (CKD) patients who undergo
haemodialysis (HD) show increased sympathetic tone
and increased serum norepinephrine levels [1–3]. In
addition, myocardial blood flow decreases significantly
during HD, indicating that acute HD-associated factors
play a role in myocardial perfusion abnormalities [4, 5].
In normal population, cardiac ischaemia and autonomic
dysfunction are reliable predictors for future cardiac
events and are also associated with increased long-term
mortality [6–8]. The presence of these findings in CKD
patients is related to a higher cardiovascular mortality,
exceeding that of age- and gender-matched healthy con-
trol subjects [9].
An unknown number of individuals with CKD are
completely asymptomatic for coronary artery disease
(CAD). Especially CKD patients with concomitant dia-
betes show silent myocardial ischaemia and diabetic auto-
nomic neuropathy. However, both the extent of cardiac
ischaemia and sympathetic innervation abnormalities as
well as the timepoint of their development during or even
before starting HD are unclear. It was previously shown
that cardiomyocytes are more vulnerable to sympathetic
innervation abnormalities than to ischaemia, which
may indicate that cardiac sympathetic innervation
abnormalities precede myocardial ischaemia, [10]. Auto-
nomic dysfunction is also commonly present in end-stage
renal disease [11], but whether this results in lack of
symptoms in cardiac ischaemia is unknown.
Thus, CKD patients undergoing HD show sympathetic
innervation abnormalities. At present, it is unclear
whether these abnormalities are present before the start of
HD or occur during the commencement of maintenance
HD. So far, the presence and severity of cardiac sympa-
thetic innervation abnormalities and CAD has never been
studied in asymptomatic end-stage (stage 5) CKD patients
who are not yet on HD. Therefore, the aim of this study is
to determine baseline cardiac sympathetic innervation in
asymptomatic stage 5 CKD patients, and to investigate the




This study was approved by the institutional ethics re-
view board (‘medisch ethische toetsingscommissie’ of the
University Medical Center Groningen, chaired by profes-
sor WA Kamps, protocol number 2008/133, date of ap-
proval June 1, 2008). All included patients gave their
written informed consent for participation in this study.
Patient information was anonymised and de-identified
before data analysis.
Between May 2010 and December 2013 a total of 18
consecutive patients (13 males and five females) with stage
5 CKD were prospectively included. Diagnosis of CKD
was based on serum levels of creatinine, and subsequent
estimated glomerular filtration rate (eGFR), the latter de-
termined by the Modification of Diet in Renal Disease
method [12]. Included were patients aged > 18 years who
had no history of CAD and were asymptomatic for
present CAD, had no history of Parkinson’s disease or de-
mentia with Lewy bodies, were not currently using tri-
cyclic antidepressant agents which could interfere with
123I-labelled meta-iodobenzylguanidine (123I-MIBG)
uptake, and were expected to start HD within the next
6 months. All patients underwent laboratory tests at
baseline. Electrocardiograms in pre-HD and during
chronic HD were retrieved from the digital patient chart.
123I-MIBG scintigraphy for cardiac sympathetic in-
nervation and 99mTc-tetrofosmin scintigraphy for myo-
cardial perfusion imaging were performed before the
start of HD and 6 months after the start of HD. Patients
who showed CAD in pre-HD were not excluded from
the study to investigate the progression of CAD during
maintenance HD. All scans were performed on interdia-
lytic days: a non-weekend day before or after an HD day.
Consensus reading on myocardial perfusion scans was
performed during general patient care board meetings.
All scans were reviewed by an experienced nuclear
medicine physician (RHJAS, with > 20 years experience),
and cardiologist (RAT, with > 20 years experience).
For 123I-MIBG imaging, nine age-matched normal
volunteers were scanned, each on one occasion, to
collect a healthy control database. All subjects were in
good health, i.e. they did not suffer from known (current
or previously treated) hypertension, heart disease, diabetes
mellitus, or renal impairment and did not use medication.
Haemodialysis
Patients were dialyzed three times per week. All patients
were on bicarbonate dialysis with a low-flux polysulfone
hollow-fiber dialyser F8 (Fresenius Medical Care, Bad
Hamburg, Germany). Blood flow and dialysate flow rates
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were 250–350 ml/min and 500 ml/min, respectively.
Dialysate temperature was 36.0 or 36.5 °C. Dialysate
composition was sodium 139 mmol/l, potassium 1.0 or
2.0 mmol/l, calcium 1.5 mmol/l, magnesium 0.5 mmol/l,
chloride 108 mmol/l, bicarbonate 34 mmol/l, acetate
3.0 mmol/l and glucose 1.0 g/dl.
123I-MIBG scintigraphy
Scintigraphy was performed after blockade of thyroid
uptake of free 123I by iodine-potassium iodide (Lugol’s
solution). After a 15-min resting period, subjects were
injected with 185 MBq (5 mCi) 123I-MIBG (General
Electric Healthcare Medical Diagnostics, Eindhoven, The
Netherlands) by an intravenous catheter. At 15 min
(early image) and 4 h (late image) after tracer adminis-
tration, a 10-min static anterior view of the chest was
acquired using a Symbia S gamma camera (Siemens
Medical System, Knoxville, Tennessee, USA) with a
medium-energy low-penetration parallel-hole collima-
tor [13]. A 15% energy window centred on 159 keV, a
256 × 256 matrix size and a 1.45 zoom factor were used.
According to guidelines for 123I-MIBG scintigraphy, the
use of β-adrenoceptor blocking agents (β-blockers) was
not discontinued [13].
For planar images, left ventricle (LV) activity was mea-
sured over the raw static image using a region of interest
along the contour of the LV. A second region of interest
was placed over the upper mediastinum [13]. The heart-
to-mediastinum ratio (HMR) was measured three times,
and the average of measurements was taken into ac-
count. Late HMR < 2.0 was considered as a sign of car-
diac sympathetic innervation abnormalities [13]. Data
were also compared with our local normal database.
99mTc-tetrofosmin SPECT
Adenosine stress 99mTc-tetrofosmin (250 MBq, 6.8 mCi)
and rest 99mTc-tetrofosmin (750 MBq, 20 mCi) electrocar-
diographically gated single-photon emission computed
tomography (SPECT) were performed in consecutive
order in a 1-day protocol to analyse myocardial ischaemia.
Patients were asked to withdraw caffeine-containing
beverages and/or food 24 h before the examination.
99mTc-tetrofosmin SPECT studies were obtained 1 h
after tracer administration using a dual-headed gamma
camera, equipped with low-energy high-resolution col-
limators (Symbia T16 gamma camera, Siemens Medical
System, Knoxville, Tennessee, USA), electrocardiographic
gating, and low-dose computed tomography for attenu-
ation correction. All data from the 99mTc-tetrofosmin
SPECT studies were reformatted to obtain short-axis,
horizontal and vertical long-axis sections. Data were ana-
lyzed and displayed in a 17-segment polar map using the
Quantitative Perfusion SPECT application, a commercially
available gated cardiac software package developed by the
Cedars-Sinai Medical Center (Los Angeles, CA, USA)
[14]. Average counts per segment were obtained from the
17 segments and the measured counts were normalized to
the segment with the highest average counts.
Statistical analysis
Baseline descriptive statistics are presented as mean ±
standard deviation or median (range) for continuous
variables and numbers with percentages for categorical
variables as required. We evaluated differences between
the two study groups using the χ2 test and Fisher exact
test for categorical data and the Student t-test and
Mann–Whitney U test for continuous data, according to
whether data were normally distributed. Furthermore, a
two-way ANOVA with Bonferroni correction for multiple
comparison was performed to analyse the differences in
study groups over time. In all analyses, p < 0.050 was
considered statistically significant. Statistical analysis
was performed using the SPSS package version 22
(IBM Corp., Armonk, NY, USA).
Results
Patient characteristics
Baseline characteristics of the patients are summarized
in Table 1. The mean age was 58 ± 18 years. For the nine
healthy controls (three males and six females), the age
(52 ± 17 years) was not significantly different (p = 0.423).
As expected in patients with stage 5 CKD, eGFR indicated
severely reduced kidney function (< 15 ml/min) in all
patients. A majority of the patients had hypertension
(78%) and used anti-hypertensive medication, mainly
β-blockers and diuretics. Diabetes mellitus was present in
33% of the patients.
At baseline, none of the patients had electrocardiographic
signs of ischaemia or infarction. One patient had a first
degree atrio-venticular block whereas another patient had a
left bundle branch block (QRS duration 138 ms).
123I-MIBG scintigraphy
Table 2 shows the results of 123I-MIBG scans. All 18 pa-
tients underwent 123I-MIBG scintigraphy in pre-HD and
during chronic HD. 123I-MIBG scans during chronic HD
were performed within 6 ± 2 months (range 3–13 months)
after the start of HD. Late HMR in patients in pre-HD
was not different from healthy controls. There was no sig-
nificant difference (especially no significant decrease) in
late HMR between pre-HD and chronic HD. However,
during chronic HD patients showed significant lower late
HMR than healthy controls: mean late HMR 2.3 vs 2.9
(p = 0.036; Fig. 1). In pre-HD, three patients had signs
of impaired cardiac sympathetic innervation, whereas
five patients showed cardiac sympathetic innervation
abnormalities during chronic HD. None of these five
patients used angiotensin converting enzyme inhibitors.
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Four of these patients did use β-blockers. Only one pa-
tient with diabetes mellitus developed cardiac sympa-
thetic innervation abnormalities during HD.
99mTc-tetrofosmin SPECT
The results of myocardial perfusion SPECT are summa-
rized in Table 3. Pre-HD myocardial perfusion SPECT
was performed in 17 out of 18 (94%) patients. One
patient was not able to undergo the investigation be-
fore the start of HD. Myocardial ischaemia was
present in six (35%) patients, and five of these six
patients also showed wall motion abnormalities, espe-
cially hypokinesia of the affected LV wall. None of
the patients had signs of infarction in pre-HD. Mean
LV ejection fraction (56 ± 17%) was within a normal
range.
Chronic HD myocardial perfusion SPECT was per-
formed within 6 ± 2 months (range 3–13 months) after
the start of HD. During chronic HD, four patients showed
myocardial ischaemia. Two of these four patients had
developed new myocardial ischaemia during HD while in
the other two patients myocardial ischaemia was already
present in pre-HD. One of these latter two patients was
an elderly lady with a prolonged history of diabetes melli-
tus. Two patients with myocardial ischaemia in pre-HD
had normal myocardial perfusion SPECT results during
chronic HD. Both patients with myocardial infarction
during chronic HD showed progression from myocardial
ischaemia in pre-HD.
During chronic HD, neither mean LV ejection fraction
nor mean end-diastolic volumes were statistically differ-
ent from pre-HD.
Relationship between myocardial perfusion and
sympathetic innervation
Four patients already had signs of cardiac sympathetic
innervation abnormalities in pre-HD. One patient with a
positive 123I-MIBG scan during chronic HD developed
new myocardial ischaemia, one patient developed an
infarction out of ischaemia in pre-HD (Figs. 2 and 3)
and one patient showed an increase in ischaemic
area. Two patients with positive 123I-MIBG scans
during chronic HD had normal myocardial perfusion
scans in pre-HD and during chronic HD. These two
patients, who showed normalization of myocardial
ischaemia in pre-HD, had no signs of cardiac sympa-
thetic innervation abnormalities in pre-HD or during
chronic HD.
Table 1 Patient characteristics at baseline
Frequency, median (range)








Diabetes mellitus 6 (33%)
Smoking 2 (11%)
Coronary artery disease 0 (0%)
Medication at baseline (number)
β-blockers 11 (61%)
ACE ihibitors 6 (33%)
Diuretics 8 (44%)
Laboratory at inclusion
Leucocytes (× 109/l) 7.1 (3.3–9.8)
Haemoglobin (mmol/l) 6.8 (6.0–9.7)
Trombocytes (× 109/l) 208 (117–347)
C-reactive protein (mg/l) 0 (0–59)
Sodium (mmol/l) 140 (135–145)
Potassium (mmol/l) 4.9 (4.0–5.9)
Chloride (mmol/l) 107 (98.0–114)
Urea (mmol/l) 26 (15–38)
Creatinine (μmol/l) 584 (339–1.31 × 103)
eGFR (ml/min × 1.73 m2) 8.0 (4.0–12)
Uric acid (mmol/l) 0.45 (0.23–0.72)
Calcium (mmol/l) 2.25 (2.07–2.53)
Phosphate (mmol/l) 1.60 (1.07–2.12)
Total protein (g/l) 67 (60–77)







Glucose (mmol/l) 6.7 (4.1–14)
Urinary protein excretion (g/24 h) 2.7 (0.40–6.8)
ACE angiotensin converting enzyme, eGFR estimated glomerular filtration rate
Table 2 123I-MIBG findings















HD haemodialysis, n number
aPatients with low late HMR and/or high washout rate
Late HMR at-follow up was significantly different from controls (p = 0.035; 95%
confidence interval of the difference −1.1, −0.46)
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Discussion
During the commencement of HD, mean late HMR was
lower than in healthy controls but not compared to pa-
tients in pre-HD. The presence of cardiac sympathetic
innervation abnormalities detected by 123I-MIBG scin-
tigraphy in HD patients is not a novel concept. However,
a statistical difference in HMR between patients and
healthy controls has never been established before [15, 16],
nor was it in this study. In addition, a difference in late
HMR between baseline and during the commencement of
maintenance HD could not be established. A previous
study showed that HMR is lower in patients undergoing
maintenance HD for a prolonged period of time, up to
120 months [17]. However, in that study 123I-MIBG
scintigraphy was performed at only one single time
point: the effect on HMR of transition from pre-HD to
HD was not investigated. The present study provides
additional information that cardiac sympathetic innerv-
ation abnormalities do not seem to worsen during the
commencement of maintenance HD.
The results of this study should be interpreted with
caution due to limited power. A power analysis was
performed and resulted in a required number of 44 in-
cluded patients. Initially, patients with CAD detected on
pre-HD myocardial perfusion SPECT were excluded
from this study. Due to a very slow inclusion of patients
with no CAD at all, we decided to also include patients
with CAD in pre-HD. This did not result in an increase
in the inclusion rate. Therefore, the study was terminated
before the necessary number of patients was included.
Eventually, only 18 patients completed the study protocol.
If the required number of patients had been included, the
results might have been more definitive. However, the
present study comprises the largest group of patients in
which cardiac sympathetic innervation has been evaluated
during the initiation of maintenance HD.
In addition, the development of myocardial perfusion
abnormalities during the commencement of mainten-
ance HD should be interpreted with caution. Patients
who showed myocardial ischaemia in pre-HD were
treated with maximal anti-ischaemic medication. The
affected areas were too small to refer for percutaneous
intervention. We cannot be sure that treatment influ-
enced the outcome of the scans during chronic HD.
Since two out of the three patients with low late HMR
in pre-HD showed alteration in myocardial perfusion
from pre-HD to chronic HD, this may suggest that car-
diac sympathetic denervation precedes the development
of myocardial perfusion defects. This suggestion sup-
ports the fact that cardiomyocytes are more susceptible
to sympathetic innervation abnormalities than to de-
creased blood flow [18]. Furthermore, two patients in
this study also developed sympathetic denervation
without myocardial perfusion abnormalities, which may
suggest (not yet detectable) microvascular coronary
dysfunction. However, six of the included 18 patients
already showed myocardial ischaemia in pre-HD
despite being asymptomatic for CAD. Then again, with
the reported small areas of myocardial ischaemia and
infarction in this cohort consisting of asymptomatic
patients, the detection rate of myocardial perfusion
SPECT was rather limited. Furthermore, cardiac mag-
netic resonance imaging seems to outperform SPECT
for the detection of CAD [19]. The reliability of the
scans of the affected ischaemic or infarcted areas could
also have been improved by performing inter-observer
agreements. Although experienced physicians reviewed
the myocardial perfusion SPECT scans in general pa-
tient care board meetings, this consensus reading is not
a substitute for inter-observer agreement analysis.
Other important issues that influence outcome are
the time between baseline scans and the start of HD
as well as the time between the start of HD and
follow-up scans. It appeared to be very difficult to de-
termine the time point for imaging, particularly in pa-
tients with very fragile kidney function. Some of the
Table 3 Gated myocardial perfusion SPECT results







137 ± 41.2 122 ± 53.2
Left ventricular
ejection fraction (%)




Fig. 1 Late 123I-MIBG heart-to-mediastinum ratio (HMR) in pre-HD
and during chronic HD, and of healthy control subjects. Late HMR
was significantly lower in patients during chronic HD than in
healthy controls
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patients had stable CKD for a prolonged period of
time but underwent sudden and rapid deterioration.
There were also patients who required the start of
HD to be postponed because the deterioration in kid-
ney function was not as rapid as expected. The lar-
gest time frame between baseline to follow-up scans
was 13 months. Unfortunately, the researchers were
not always aware of this change in schedule. There-
fore, uncertainty about the start of HD resulted in
the differences in the time-interval of imaging.
According to the 2012 United States Renal Data
System annual report, arrhythmia and sudden cardiac
arrest accounted for 63% of the cardiovascular and
27% of all-cause mortality in dialysis patients [20]. In a
recent study involving 75 HD patients with an im-
plantable cardioverter defibrillator (ICD), nearly 80%
of all sudden cardiac arrests were caused by ventricular
tachycardia and ventricular fibrillation [21]. The au-
thors reported a higher survival rate after sudden car-
diac arrest than previously assumed. 123I-MIBG scans
are known to have predictive implications for success-
ful ICD therapy in patients with heart failure [22].
Therefore, 123I-MIBG scintigraphy has the potential to
play a guiding role in clinical ICD decision-making in
HD patients. Until that time, prospective studies have
to demonstrate the relationship between low late HMR
and the development of ischemic heart failure-related
arrhythmia during HD.
To summarise, stage 5 CKD patients on maintenance
HD showed a lower mean late HMR than healthy con-
trols. Mean late HMR does not seem to worsen after
the commencement of HD or during maintenance HD.
Although present in a minority of the patients, signs of
cardiac sympathetic innervation abnormalities in pre-
HD may lead to alterations in myocardial perfusion
during chronic HD. Further prospective studies should
provide more insight into the long-term effect of car-
diac sympathetic innervation abnormalities on the de-
velopment of ischaemic heart failure-related arrhythmia
during HD.
Fig. 2 Polar map reconstruction of the myocardial perfusion SPECT of a patient during chronic HD: a stress image; b rest image. The persisting
perfusion defect in the antero-apical segments of the left ventricle wall (red arrows) indicates myocardial infarction
Fig. 3 Planar images from 123I-MIBG scintigraphy of a patient during chronic HD. a Early image 15 min after tracer administration; b late
image 4 h after tracer administration. Late heart-to-mediastinum ratio (HMR) is the ratio between the counts within a reference point in
the upper mediastinum (red square box) and the left ventricle (red contoured region). The HMR of panel a was 3.03 and of panel b 1.80,
resulting in a 41% washout
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